Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CHMP recommends Rebif use in patients with early signs of MS

This article was originally published in Scrip

Executive Summary

Experts on the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) are recommending that the terms of the European market authorisation of Rebif (interferon beta-1a) should be amended to treat patients with early signs of multiple sclerosis. The CHMP is recommending that 44 micrograms of Rebif three times weekly should be given to patients who have experienced a single demyelinating event, an early sign of multiple sclerosis, and who are at high risk of developing the disease.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC015270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel